Assertio therapeutics, inc. revises earnings guidance for the full year 2019

Assertio therapeutics, inc. revised earnings guidance for the full year 2019. the company is raising its previous 2019 earnings guidance range and lowering its neurology franchise net sales guidance to $102 to $105 million. the company expected net loss to be in the range of $47 million to $42 million compared to previously expected range of $68 million to $58 million.
ASRT Ratings Summary
ASRT Quant Ranking